Hydroxychloroquine is associated with lower seroconversion upon 17DD-Yellow fever primovaccination in patients with primary Sjögren’s syndrome

Hydroxychloroquine is associated with lower seroconversion upon 17DD-Yellow fever primovaccination in patients with primary Sjögren’s syndrome

The present study aimed at investigating whether the hydroxychloroquine (HCQ) treatment would impact the neutralizing antibody production, viremia levels and the kinetics of serum soluble mediators upon planned 17DD-Yellow Fever (YF) primovaccination (Bio-Manguinhos-FIOCRUZ) of primary Sjögren’s syn...

Full description

Saved in:
Bibliographic Details
Main Authors: Ketty Lysie Libardi Lira Machado, Ismael Artur da Costa-Rocha, Laura Gonçalves Rodrigues Aguiar, Isac Ribeiro Moulaz, Samira Tatiyama Miyamoto, Priscila Costa Martins, Erica Vieira Serrano, Ana Paula Espíndula Gianordoli, Maria da Penha Gomes Gouvea, Maria de Fatima Bissoli, Sheila Maria Barbosa de Lima, Waleska Dias Schwarcz, Adriana de Souza Azevedo, Juliana Fernandes Amorim da Silva, Renata Tourinho Santos, Joaquim Pedro Brito-de-Sousa, Jordana Grazziela Coelho-dos-Reis, Ana Carolina Campi-Azevedo, Andréa Teixeira-Carvalho, Vanessa Peruhype-Magalhães, Francieli Fontana Sutile Tardetti Fantinato, Licia Maria Henrique da Mota, Olindo Assis Martins-Filho, Valéria Valim
Format: Article
Language:English
Published: Taylor & Francis Group 2024-12-01
Series:Human Vaccines & Immunotherapeutics
Subjects:
Primary Sjögren’s syndrome
hydroxychloroquine
17DD-YF vaccine
humoral immunity
serum biomarkers
Online Access:https://www.tandfonline.com/doi/10.1080/21645515.2024.2318814
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:The present study aimed at investigating whether the hydroxychloroquine (HCQ) treatment would impact the neutralizing antibody production, viremia levels and the kinetics of serum soluble mediators upon planned 17DD-Yellow Fever (YF) primovaccination (Bio-Manguinhos-FIOCRUZ) of primary Sjögren’s syndrome (pSS). A total of 34 pSS patients and 23 healthy controls (HC) were enrolled. The pSS group was further categorized according to the use of HCQ (HCQ and Non-HCQ). The YF-plaque reduction neutralization test (PRNT ≥1:50), YF viremia (RNAnemia) and serum biomarkers analyses were performed at baseline and subsequent time-points (Day0/Day3–4/Day5–6/Day7/Day14-D28). The pSS group showed PRNT titers and seropositivity rates similar to those observed for HC (GeoMean = 238 vs 440, p = .11; 82% vs 96%, p = .13). However, the HCQ subgroup exhibited lower seroconversion rates as compared to HC (GeoMean = 161 vs 440, p = .04; 69% vs 96%, p = .02) and Non-HQC (GeoMean = 161 vs 337, p = .582; 69% vs 94%, p = .049). No differences in YF viremia were observed amongst subgroups. Serum biomarkers analyses demonstrated that HCQ subgroup exhibited increased levels of CCL2, CXL10, IL-6, IFN-γ, IL1-Ra, IL-9, IL-10, and IL-2 at baseline and displayed a consistent increase of several biomarkers along the kinetics timeline up to D14–28. These results indicated that HCQ subgroup exhibited a deficiency in assembling YF-specific immune response elicited by 17DD-YF primovaccination as compared to Non-HCQ subgroup. Our findings suggested that hydroxychloroquine is associated with a decrease in the humoral immune response after 17DD-YF primovaccination.
ISSN:2164-5515
2164-554X

Similar Items